Hospital-acquired Infections Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

Hospital-acquired Infections size is expected to grow significantly from 2019 to 2025.
 

Increasing elderly population with low physical immunity that are prone to infections, poor condition of healthcare administrations and poor hygiene standards, vulnerability of patient’s immunity, presence of other diseases, are some of the major factors contributing towards the growth of hospital-acquired treatment market. The environmental factors such as infected material and bacterial load in hospitals, crowding and humidity, temperature, patient’s age, increasing chronic diseases, lack of awareness, are some of factors propelling the prevalence of hospital-acquired infections.
 

Growing threat of antibiotic-resistant along with growing hospital admissions are expected to drive the growth of hospital-acquired infection market. According to WHO, about 8.7% of patients admitted to hospital had nosocomial infections affecting about 1.4 million people globally. The increasing number of patients with hospital-acquired infection is anticipated to spur market growth substantially during the forecast period. However, higher generic penetration owing to patent loos of drugs, vast fragmentation of market and companies operating in the market, growing utilization of quality building material namely ceramics and glass in constructions, are some factors hindering the market growth.
 

Urinary tract infection (UTI) accounts for significant market share in the hospital-acquired infections market in 2018. According to the National Healthcare Safety Network (NHSN), UTI is most common hospital-acquired infection affecting millions of people globally. Among them, about 75% of infections are associated with urinary catheters. About 15-25% of patients admitted to hospitals require urinary catheters, and that is increasing prevalence of these infections and further propelling the market growth.
 

The antibacterial treatment segment should witness significant growth in the hospital-acquired infections market during forecast period. The bacterial infections are the most commonly occurred in hospitals, and therefore the segment is expected to generate substantial growth over forecast period.
 

The retail pharmacy segment is estimated to hold a dominating share in the hospital-acquired infections market in 2018. The presence of a large number of retail pharmacies, ease of availability of medicines, are some of the factors contributing to the high share of the segment in the global hospital-acquired infections market.
 

The retail pharmacy segment is estimated to hold a dominating share in the hospital-acquired infections market in 2018. The presence of large number of retail pharmacies, ease of availability of medicines, are the factors contributing towards high share of segment in the global hospital acquired infections market.
 

Asia Pacific is estimated to register a significant CAGR in hospital-acquired infections market over the forecast period. The key factors responsible for growth of region are rapidly growing prevalence of hospital-acquired infections, owing to inappropriate sterilization treatment, and unhygienic environments. Growing efforts by the government to increase awareness about hospital-acquired infections will significantly propel the Asia Pacific hospital-acquired infections market growth during the forecast period. moreover, increasing healthcare expenditure, growing hospital admissions owing to the increasing incidence of chronic diseases will significantly drive the market growth.
 

Some of the major players operating in the hospital-acquired infections industry include Pfizer, Abbott, Bayer, AstraZeneca, Cepheid, F. Hoffmann-La Roche, Merck, Johnson & Johnson, Cipla, Daiichi Sankyo, GlaxoSmithKline, Eli Lilly and Company, and Bristol-Myers Squibb. The market for hospital-acquired infections is defined by the geographical expansion of key players in the emerging nations. Furthermore, an increasing number of product launches, strategic acquisitions, and mergers and the rising dominance of leading players will spur the market growth during the forecast period. Also, large drugs pipeline and approval of these drugs may generate growth opportunities in the hospital-acquired infections market. For instance, in June 2019, the U.S. FDA has approved a new indication for Zerbaxa, the formerly FDA-approved drug, for treatment of ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia (VABP/ HABP) in patients 18 years and above. The newer introduction is expected to strengthen the existing product portfolio of the market and this will spur the growth of the market over the forecast period. 
 

Hospital-acquired Infections Market By Infection Type, 2014-2025 (USD Million)

• Ventilator Associated Pneumonia
• Urinary Tract Infections
• Bloodstream Infections
• Surgical Site Infections
• Other Hospital Infections

Hospital-acquired Infections Market By Treatment, 2014-2025 (USD Million)

• Antibacterial Treatment
• Antiviral Treatment
• Antifungal Treatment
• Others

Hospital-acquired Infections Market By Distribution Channel, 2014-2025 (USD Million)

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacy
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
• Latin America
  • Mexico
  • Brazil
• Middle East and Africa
  • Saudi Arabia
  • South Africa

Company Profiles:

• Pfizer
• Abbott
• Bayer
• AstraZeneca
• Cepheid
• F. Hoffmann-La Roche
• Merck
• Johnson & Johnson
• Cipla
• Daiichi Sankyo
• GlaxoSmithKline
• Eli Lilly and Company
• Bristol-Myers Squibb

What Information does this report contain?